. "illicit"@en . . "Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia. Regular use leads to tolerance, and it is usually not effective for more than 7 days. Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates."@en . . . "Junkmann, K. and Pfeiffer, H.; US. Patent 2,816,910; December 17, 1957; assigned to Schering AG, Germany."@en . . "Symptoms of overdose include shortness of breath or slow or troubled breathing, slow heartbeat, severe weakness, chronic confusion, slurred speech, and staggering."@en . "Rapidly absorbed following oral administration."@en . "Etinamato"@en . . . . "Humans and other mammals"@en . . "The mechanism of action is not known. However, studies have shown that ethinamate inhibits carbonic anhydrases I and II (J Biol Chem. 1992 Dec 15;267(35):25044-50). This inhibition by ethinamate is not sufficiently strong, however, to implicate carbonic anhydrases I and II in the mechanism of action."@en . . "Ethinamatum"@en . . . . . . . . . "approved"@en . "2.5 hours"@en . . . "withdrawn"@en . . . . . . . . "Ethinamate"@en . . . "1-Ethynylcyclohexanol carbamate"@en . . . "Ethinamate"@en . . . "Aethinyl-cyclohexyl-carbamat"@en . "126-52-3"@en . . "Used for the short-term treatment of insomnia, however, it generally has been replaced by other sedative-hypnotic agents."@en . . . . . . . . .